- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.03. | Lixte stock soars on preclinical data for lead drug LB-100 | 4 | Seeking Alpha | ||
| 22.03. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 21.03. | Lixte Biotechnology Holdings, Inc.: LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments | 124 | GlobeNewswire (Europe) | -- Three Clinical Trials Currently Underway for Treating Ovarian, Lung and Sarcoma Cancers -- PASADENA, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the... ► Artikel lesen | |
| 19.03. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 10-K, Annual Report | 1 | SEC Filings | ||
| 26.02. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 26.02. | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI | 358 | GlobeNewswire (Europe) | Agreement Focuses on Combining LIXTE's LB-100 with Various Innovative Cancer Immunotherapies PASADENA, CA, Feb. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW)... ► Artikel lesen | |
| 13.02. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 13.02.2024 - 4 | 4.356 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 13.02.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 13.02.2024ISIN NameUS42328V8019 HELIUS... ► Artikel lesen | |
| 29.01. | Lixte Biotechnology Holdings, Inc.: First Patient Dosed with LIXTE's LB-100 and GSK's Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial | 246 | GlobeNewswire (Europe) | PASADENA, CA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) ("LIXTE" or the "Company"), today announced the dosing of the first patient in a Phase 1b/2... ► Artikel lesen | |
| 28.11.23 | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.11.23 | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 13.11.23 | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations | 639 | GlobeNewswire (Europe) | PASADENA, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new... ► Artikel lesen | |
| 09.11.23 | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 03.11.23 | IFRX, LIXT and IOAC are among pre market gainers | 33 | Seeking Alpha | ||
| 26.09.23 | Lixte Biotechnology Holdings, Inc.: LIXTE Appoints Bas van der Baan as President and Chief Executive Officer | 405 | GlobeNewswire (Europe) | Biotechnology Veteran Bas van der Baan Brings Precision Oncology Expertise; Founder John S. Kovach Named Executive Chairman PASADENA, CA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings... ► Artikel lesen | |
| 23.06.23 | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing Requirements | 346 | GlobeNewswire (Europe) | PASADENA, CA, June 23, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) ("LIXTE" or the "Company") announced today that it has received confirmation from The Nasdaq Stock... ► Artikel lesen | |
| 06.06.23 | XFRA 8640: AUSSETZUNG/SUSPENSION | 358 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILLIXTE BIO.HLDGS... ► Artikel lesen | |
| 06.06.23 | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 06.06.2023 | 567 | Xetra Newsboard | The following instruments on XETRA do have their first trading 06.06.2023 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 06.06.2023
Aktien
1 GRS469003024 Kri-Kri Milk Industry... ► Artikel lesen | |
| 05.06.23 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 05.06.2023 | 543 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 05.06.2023.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 05.06.2023.ISIN NameCA03835T2002 APTOSE... ► Artikel lesen | |
| 05.06.23 | XFRA ISIN CHANGE | 802 | Xetra Newsboard | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenUS5393192027 Lixte Biotechnology Holdings Inc. 05.06.2023 US5393193017 Lixte Biotechnology Holdings Inc. 06.06.2023... ► Artikel lesen | |
| 05.06.23 | XFRA 864: AUSSETZUNG/SUSPENSION | 229 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILLIXTE BIOTECHN.... ► Artikel lesen |
Seite:
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| OCUGEN | 1,180 | -1,01 % | Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards? | ||
| MAINZ BIOMED | 0,774 | +0,52 % | Mainz Biomed: Studienerfolg, aber leere Taschen - was nun? | Ein vertrautes Muster: Mainz Biomed (WKN: A3C6XX) feiert trotz fast leerer Kassen Forschungserfolge, doch die Aktie stürzt immer weiter ab. Das ist nicht nur für Aktionäre tragisch, da das Forschungsgebiet... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,493 | +1,50 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering | Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has entered into a securities purchase agreement with institutional investors, providing for the purchase... ► Artikel lesen | |
| TREVENA | 0,391 | +4,83 % | TREVENA INC - 8-K, Current Report | ||
| AFFIMED | 4,620 | -1,70 % | Affimed N.V.: Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology | The preliminary results from the phase 2 study investigating AFM24 in combination with the checkpoint inhibitor atezolizumab in patients with EGFR wild-type non-small cell lung cancer have been accepted... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 0,682 | +1,34 % | Phio Pharmaceuticals Corp.: Intratumoral Injection of Phio's PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells | -Injection in murine tumors shows the compound is well tolerated -Studies support ongoing clinical trial of PH-762 as a neoadjuvant therapy for treatment of cSCC, melanoma, or Merkel cell carcinoma... ► Artikel lesen | |
| MARINOMED BIOTECH | 18,150 | -0,27 % | Marinomed Biotech: Solv4U-Kooperation mit Aché Laboratórios | Marinomed Biotech meldet eine neue Zusammenarbeit: Man habe eine Solv4U-Forschungs- und Entwicklungskooperation mit Aché Laboratórios Farmaceuticos aus Brasilien abgeschlossen, so das österreichische... ► Artikel lesen | |
| IMMUNITYBIO | 6,800 | -0,96 % | Pre-market Movers: Abeona Therapeutics, HWH International, ImmunityBio, Hibbett, AGBA Group | NORWALK (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.55 A.M. ET).In the Green HWH International Inc. (HWH) is up over 42% at $1.83.
ImmunityBio... ► Artikel lesen | |
| EMERGENT BIOSOLUTIONS | 1,788 | -0,67 % | Emergent BioSolutions Inc. - 8-K, Current Report | ||
| ORAGENICS | 1,030 | -10,43 % | Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards | SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced... ► Artikel lesen | |
| FRESH TRACKS THERAPEUTICS | 0,730 | 0,00 % | Fresh Tracks Therapeutics, Inc.: Fresh Tracks Therapeutics Urges Stockholders to Vote at the Upcoming Special Meeting on February 15th | Stockholders of record on January 11, 2024 who have not yet voted are encouraged to do so by 11:59 p.m. Eastern Time on February 14, 2024 BOULDER, Colo., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Fresh Tracks... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 2,384 | -2,30 % | BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting | Poster presentation scheduled for June 1, 2024, 1:30-4:30 PM CT /2:30-5:30 PM ET Trial being led by Georgetown University's Lombardi Comprehensive Cancer Center NEW HAVEN, Conn., April 24, 2024 (GLOBE... ► Artikel lesen | |
| LEXICON PHARMACEUTICALS | 1,503 | +1,42 % | Lexicon Pharmaceuticals, Bio-Path Holdings, Protara Therapeutics among healthcare movers | ||
| CHIMERIX | 0,842 | +0,36 % | Chimerix, Inc.: Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024 | ||
| CARA THERAPEUTICS | 0,678 | +6,19 % | Cara Therapeutics, Inc.: Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results | -Announced prioritization of clinical programs to focus on late-stage development of oral difelikefalin for notalgia paresthetica (NP)- -Completed enrollment of KOURAGE 1 Part A portion of NP pivotal... ► Artikel lesen |
LIXTE BIOTECHNOLOGY HOLDINGS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 3,140 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
